Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 14/20 | 0.66 |
| ▸ | INSR | P06213 | 11/20 | 0.66 |
| ▸ | IGF1R | P08069 | 11/20 | 0.66 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.60 |
| ▸ | PLK1 | P53350 | 4/20 | 0.60 |
| ▸ | EGFR | P00533 | 3/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | STK10 | O94804 | 1/20 | 0.56 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.56 |
| ▸ | SLC34A2 | O95436 | 1/20 | 0.56 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | CD74 | P04233 | 1/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | FES | P07332 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21099441 | 0.95 | PLK1 (0.62) | ALKINSRIGF1RPTK2PLK1 | |
| SCHEMBL21099503 | 0.94 | ALK (0.60) | ALKINSRIGF1RPTK2PLK1 | |
| SCHEMBL19867298 | 0.93 | ALK (0.65) | ALKINSRIGF1RPTK2PLK1 | |
| SCHEMBL19867318 | 0.91 | ALK (0.63) | ALKINSRIGF1RPTK2PLK1 | |
| SCHEMBL21099508 | 0.89 | IRAK4 (0.54) | ALKINSRIGF1RPTK2PLK1 | |
| SCHEMBL21099604 | 0.88 | ALK (0.59) | ALKINSRIGF1RPTK2PLK1 | |
| SCHEMBL19921168 | 0.87 | ALK (0.65) | ALKINSRIGF1RPTK2PLK1 | |
| SCHEMBL19867180 | 0.87 | ALK (0.75) | ALKINSRIGF1RPTK2PLK1 | |
| SCHEMBL21099421 | 0.87 | ALK (0.63) | ALKINSRIGF1RPTK2PLK1 | |
| SCHEMBL21150639 | 0.87 | PTK2 (0.60) | ALKINSRIGF1RPTK2PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078213-B2 | Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof | Hongyun Biotech Co., Ltd. (CN) | 2021-08-03 | — | — | US | disclosed |
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2020-07-02 | — | — | US | disclosed |
| US-20190211030-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2019-07-11 | — | — | US | disclosed |
| EP-3498716-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS | Hongyun Biotech Co., Ltd. (CN) | 2019-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190211030-A1 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ALK, MET, TIE1 | ALK 1/4885INSR 2213/4885IGF1R 975/4885 |
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ALK, MET, TIE1 | ALK 1/4885INSR 2213/4885IGF1R 975/4885 |
| US-11078213-B2 | Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof | ALK, MET, TIE1 | ALK 1/4885INSR 2213/4885IGF1R 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.